2024-01 – Q4 2023 Reporting
After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down. Recruitment of patients in Australia remains very…
After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down. Recruitment of patients in Australia remains very…
Screening of patients in New Zealand improved after visiting the clinical centres involved in SER150 CL-009 study. The broaden of inclusion criteria for recruitment of patients to theSER150 CL-009 study…
Screening of patients in New Zealand has now improved after visiting the clinical centres involved in SER150 CL-009 study. To facilitate enrolment, the entrance criteria will be revised for the…
Address: Stokholmsgade 412100 Copenhagen E June 21, 2023, at 15:00Please reserve the date
Read more here Norwegian VPS registred shareholders: VPS General Meeting
Serodus ASA - Publishes 2022 Annual Report Download it here
Serodus has visited all clinical centers in Australia and New Zealand SER150/placebo dosing period has been prolonged from 3 to 6 months. Read more here
New Zealand authorities approved the protocol with dosing of SER150 or placebo for six months. All clinical centers in Australia and New Zealand ready to initiate screening of patients in…